Spots Global Cancer Trial Database for A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
Official Title: A Prospective, Multicenter, Open-label Comparison of Pre-surgical Myocet/ Cyclophosphamide (MC) q3w Followed by Either MC or Paclitaxel - Depending on Early Response Assessment by Ultrasound or by Toxicity for Elderly Non Frail Primary Breast Cancer Patients With Increased Risk of Relapse.
Study ID: NCT02214381
Conditions
Study Description
Brief Summary: Comparison of pre-surgical Myocet/ Cyclophosphamide (MC) q3w followed by either MC or Paclitaxel - depending on early response assessment by ultrasound or by toxicity for elderly non frail primary breast cancer patients with increased risk of relapse.
Detailed Description:
Keywords
Eligibility
Minimum Age: 70 Years
Eligible Ages: OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Moenchengladbach, , Germany
Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich, , Germany
Contact Details
Name: Nadia Harbeck, Prof. Dr.
Affiliation: Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich, Germany
Role: PRINCIPAL_INVESTIGATOR
Name: Ulrike Nitz, Prof. Dr.
Affiliation: Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, Germany
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
